Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3971455 | 0.99 | KMT2A (0.45) | KMT2AMEN1CTDSP1HTTSORT1 | |
| SCHEMBL3979023 | 0.82 | AAK1 (0.41) | KMT2AMEN1CTDSP1HTTMAPK1 | |
| SCHEMBL1342083 | 0.82 | MAP2K1 (0.53) | KMT2AMEN1CTDSP1HTTSORT1 | |
| SCHEMBL3973198 | 0.79 | KMT2A (0.44) | KMT2AMEN1CTDSP1HTTSORT1 | |
| SCHEMBL13842076 | 0.77 | KMT2A (0.43) | KMT2AMEN1CTDSP1SORT1MAPK1 | |
| SCHEMBL13842024 | 0.77 | MAP2K1 (0.49) | KMT2AMEN1CTDSP1HTTSORT1 | |
| SCHEMBL17134758 | 0.76 | RAB9A (0.49) | KMT2AMEN1MAPK1KDM4ENPC1 | |
| SCHEMBL30379619 | 0.76 | MAPT (0.55) | KMT2AMEN1DHODH | |
| SCHEMBL21600853 | 0.76 | MAPT (0.55) | KMT2AMEN1DHODH | |
| SCHEMBL2882409 | 0.75 | FBP1 (0.40) | KMT2AMEN1CTDSP1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7144907-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KMT2A 1998/4885MEN1 1323/4885CTDSP1 3033/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KMT2A 2008/4885MEN1 1465/4885CTDSP1 2953/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KMT2A 2278/4885MEN1 1542/4885CTDSP1 3137/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KMT2A 2008/4885MEN1 1465/4885CTDSP1 2953/4885 |
| US-20100331334-A1 | INHIBITORS OF MEK | NRAS, BRAF, KSR2 | KMT2A 254/4885MEN1 1653/4885CTDSP1 2005/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | KMT2A 4321/4885MEN1 4629/4885CTDSP1 3456/4885 |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | NRAS, BRAF, RAF1 | KMT2A 1580/4885MEN1 906/4885CTDSP1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.